Our findings suggests that CHEK2 germ line mutations play a negligible role in early-onset and familial breast/ovarian cancer in Pakistan and imply that CHEK2 mutation screening of high-risk patients is not warranted in this population. The gene discussed is CHEK2; the disease is ovarian carcinoma.